

Our findings reaffirm the importance of immunising the youngest infants who bear the greatest burden of severe RSV outcomes. Our estimates should allow more precise quantification of the potential impact of RSV prevention strategies across the full range of RSV disease severity in children younger than 5 years.
Child & Adolescent Health
|11th Mar, 2026
|The Lancet
Child & Adolescent Health
|11th Mar, 2026
|The Lancet
Child & Adolescent Health
|11th Mar, 2026
|The Lancet
Child & Adolescent Health
|11th Mar, 2026
|The Lancet
Child & Adolescent Health
|11th Mar, 2026
|The Lancet
Child & Adolescent Health
|11th Mar, 2026
|The Lancet
Child & Adolescent Health
|11th Mar, 2026
|The Lancet